{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"141"}]}],"title":"Improved"},{"categories":[{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"136"}]}],"title":"Unchanged"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"}]}],"title":"Worsened"}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"294"}],"units":"Participants"}],"description":"The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on physical component were summed and averaged (range 0 \\[worst\\] to 100 \\[best\\]); If participants' had shown change from baseline in physical health component score \\>5.42, it was considered as improved; score between -5.42 to 5.42 was considered as unchanged, and score \\< -5.42 was considered as worsened. Change from Baseline = difference between the score of physical component at Week 24 and the score at Baseline.","groups":[{"description":"Eligible participants were administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to 24 weeks and were followed up to Week 104.","id":"OG000","title":"Placebo Plus Methotrexate"},{"description":"Eligible Participants were administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and were followed up to Week 104.","id":"OG001","title":"Rituximab Plus Methotrexate"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized participants who received any part of an infusion of study drug. Participants with available data at the time of evaluation were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline (Day 1) to Week 24","title":"Number of Participants With Categorical Change From Baseline in the Physical Component Scores of SF-36","type":"SECONDARY","unitOfMeasure":"participants"}